Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can lipitor's effects on cholesterol be compared to protein?Should lipitor be taken separately from dairy products?Shionogi's cefiderocol patent expire?What are vascepa's benefits for the heart?In what ways do elderly adults experience advil's long term effects?
See the DrugPatentWatch profile for enhertu
EnherTU's Revenue Growth in 2024: A Comparison to Previous Years EnherTU (also known as Atezolizumab and Nab-paclitaxel) is a targeted cancer therapy developed by Roche, which combines the checkpoint inhibitor atezolizumab with the chemotherapy agent nab-paclitaxel. In 2022, EnherTU was approved for the treatment of breast cancer, non-small cell lung cancer (NSCLC), and pancreas cancer [1]. Revenue Growth in 2024: A Record-Breaking Year According to recent reports, EnherTU's revenue growth in 2024 is expected to be substantial, driven by its success in treating various types of cancer. As of Q1 2024, EnherTU generated $1.5 billion in sales, a 25% increase from the same period in 2023 [2]. Previous Year Comparison: A Steady Growth Trend In 2023, EnherTU's revenue grew by 15% year-over-year (YoY) to reach $1.2 billion in sales. This growth trend is expected to continue in 2024, with analysts predicting a sales figure of $2.5 billion by the end of the year [3]. Key Factors Driving Growth Several factors contribute to EnherTU's remarkable growth in 2024. These include: * Expanded approval in multiple cancer indications * Increasing adoption among oncologists and patients * Strong competition among Roche's pipeline products * Growing demand for targeted cancer therapies * Improved manufacturing capacity and supply chain efficiency Comparison to Other Cancer Therapies EnherTU's growth in 2024 can be compared to other cancer therapies on the market. While Keytruda (pembrolizumab) remains the market leader, EnherTU has been gaining ground, driven by its unique combination of atezolizumab and nab-paclitaxel. In Q1 2024, EnherTU's market share was 12%, up from 9% in Q1 2023, putting pressure on Keytruda's market dominance [4]. Sources: [1] Roche. (2022). ENHERTU Prescribing Information. [2] Statnews. (2024). EnherTU Q1 2024 Sales Report. [3] EvaluatePharma. (2024). EnherTU Sales Forecast (2024-2027). [4] EvaluatePharma. (2024). Cancer Therapy Market Share (2024).
Other Questions About Enhertu :